3-deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 2915-2918

  Shen, Liang ^a   Cui, Jing ^c   Pang, Ying Xin ^b   Ma, Yan Hui ^b   Liu, Pei Shu ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c JINAN STOMATOLOGICAL HOSPITAL   (China)

Author keywords

Apoptosis; DZNep; Migration; Ovarian cancer cells; Proliferation

Indexed keywords

3-DEAZANEPLANOCIN; ADENOSINE; ANTINEOPLASTIC AGENT; CADHERIN; ENZYME INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; MTF2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; HUMAN; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ADENOSINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; OVARIAN NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84880380878     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.2915     Document Type: Article

References (18)

1. Bristow RE, Palis BE, Chi DS, et al (2010). The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol, 118, 262-7.
2. Cao R, Wang L, Wang H, et al (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science, 298, 1039-43.
3. Danial NN, Korsmeyer SJ (2004). Cell death: critical control points. Cell, 116, 205-19.
4. Davies BR, Worsley SD, Ponder BA (1998). Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology, 32, 69-80.
5. Glazer RI, Hartman KD, Knode MC, et al (1986). 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun, 135, 688-94.
6. Guo J, Cai J, Yu L, et al (2011). EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci, 102, 530-9.
7. Hudson LG, Zeineldin R, Stack MS (2008). Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis, 25, 643-55.
8. Imai T, Horiuchi A, Shiozawa T, et al (2004). Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol, 35, 1469-76.
9. Kalushkova A, Fryknäs M, Lemaire M, et al (2010). Polycomb target genes are silenced in multiple myeloma. PLoS One, 5, e11483.
10. Kikuchi J, Takashina T, Kinoshita I, et al (2012). Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer, 78, 138-43.
11. Kuzmichev A, Nishioka K, Erdjument-Bromage H, et al (2002). Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev, 16, 2893-905.
12. Landen CN Jr, Birrer MJ, Sood AK (2008). Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol, 26, 995-1005.
13. Liu S, Wolfe MS, Borchardt RT (1992). Rational approaches to the design of antiviral agents based on S-adenosyl-Lhomocysteine hydrolase as a molecular target. Antiviral Res, 19, 247-65.
14. Orrenius S, Zhivotovsky B, Nicotera P (2003). Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol, 4, 552-65.
15. Rao ZY, Cai MY, Yang GF, et al (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis, 31, 1576-83.
16. Rizzo S, Hersey JM, Mellor P, et al (2011). Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther, 10, 325-35.
17. Sasaki D, Imaizumi Y, Hasegawa H, et al (2011). Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica, 96, 712-19.
18. Tan J, Yang X, Zhuang L, et al (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev, 21, 1050-63.